Cochrane · systematic review · CD009472
Sulthiame add‐on therapy for epilepsy
Bresnahan, R, Martin‐McGill, KJ, Milburn‐McNulty, P, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsSulthiame add‐on compared to placebo for epilepsy (event)
Population: patients between 3 to 15 months of age with West syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency Sulthiame add‐on vs placebo | no estimate extracted | NR | No studies |
Complete cessation of seizures during Sulthiame add‐on vs placebo | RR 11.14 [0.67, 184.47] | 1 study · 37 participants | Very low Downgraded: risk of bias |
Mean seizure frequency Sulthiame add‐on vs placebo | no estimate extracted | NR | No studies |
Time‐to‐treatment withdrawal Sulthiame add‐on vs placebo | no estimate extracted | NR | No studies |
Adverse effects: total number of participants experiencing one or more adverse effects Sulthiame add‐on vs placebo | RR 0.85 [0.44, 1.64] | 1 study · 37 participants | Very low Downgraded: risk of bias |
Adverse effects: somnolence Sulthiame add‐on vs placebo | RR 3.4 [0.42, 27.59] | 1 study · 37 participants | Very low Downgraded: risk of bias |
Quality of life Sulthiame add‐on vs placebo | no estimate extracted | NR | No studies |